obesity

Vivus obesity pill prescriptions jump 68 percent, shares rise

Vivus obesity pill prescriptions jump 68 percent, shares rise

Reuters

And the Obesity Plot Thickens

And the Obesity Plot Thickens

Motley Fool

Takeda and Amylin terminate obesity compound co-development agreement

Takeda and Amylin terminate obesity compound co-development agreement

equities.com

Key Dates For Arena And Orexigen Investors

Key Dates For Arena And Orexigen Investors

Seeking Alpha

Does Qsymia Have a Future After All?

Does Qsymia Have a Future After All?

Wall Street Cheat Street

Vivus Rises On Wider Coverage Of Qsymia

Vivus Rises On Wider Coverage Of Qsymia

Seeking Alpha

Orexigen: Is Contrave The Long-Term Winner In The Anti-Obesity Drug Wars?

Orexigen: Is Contrave The Long-Term Winner In The Anti-Obesity Drug Wars?

Seeking Alpha

Vivus shares jump on strong growth in Qsymia prescriptions

Vivus shares jump on strong growth in Qsymia prescriptions

Reuters

Investor Enthusiasm Wanes For Obesity Drug Companies

Investor Enthusiasm Wanes For Obesity Drug Companies

Seeking Alpha

The Looming EU Approval Makes Arena Pharmaceuticals Significantly Undervalued

The Looming EU Approval Makes Arena Pharmaceuticals Significantly Undervalued

Motley Fool